Literature DB >> 21443494

The clinical utility of the protamine 1/protamine 2 ratio in sperm.

Laszlo Nanassy1, Lihua Liu, Jeanine Griffin, Douglas T Carrell.   

Abstract

During spermiogenesis, human sperm undergo a dramatic reorganization of the chromatin in which canonical histones are replaced by two types of protamines, protamine 1 (P1) and protamine (P2). P1 and P2 are expressed approximately at a 1:1 ratio in healthy men. Alteration of this ratio is associated with male infertility. Patients with an abnormal P1/P2 ratio generally exhibit diminished semen quality, lower fertilization ability, and lower pregnancy rates when undergoing in vitro fertilization. Many studies have reported an elevated incidence of abnormal P1/P2 ratios in infertile men compared to fertile controls, and have evaluated the relationship between infertility and abnormal protamination; however, no prospective study has investigated the normal range of the P1/P2 ratio in men from the general population. Here, we report a P1/P2 reference range of 0.54 to 1.43 in a fertile, normozoospermic population. This rather wide normal range of P1/P2 led us to the conclusion that abnormal protamination is more likely indicative of other perturbations during spermatogenesis than the underlying mechanism to cause infertility. Alternatively, protamine expression may act as a checkpoint mechanism and thus be indirectly related to semen quality.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21443494     DOI: 10.2174/092986611795713934

Source DB:  PubMed          Journal:  Protein Pept Lett        ISSN: 0929-8665            Impact factor:   1.890


  17 in total

Review 1.  The role of epigenetics in spermatogenesis.

Authors:  Sezgin Güneş; Tuba Kulaç
Journal:  Turk J Urol       Date:  2013-09

Review 2.  Paternal factors contributing to embryo quality.

Authors:  Stacy Colaco; Denny Sakkas
Journal:  J Assist Reprod Genet       Date:  2018-09-11       Impact factor: 3.412

3.  Proteomic Analysis Reveals that Topoisomerase 2A is Associated with Defective Sperm Head Morphology.

Authors:  Jacob Netherton; Rachel A Ogle; Louise Hetherington; Ana Izabel Silva Balbin Villaverde; Hubert Hondermarck; Mark A Baker
Journal:  Mol Cell Proteomics       Date:  2019-12-17       Impact factor: 5.911

4.  Association of 25-hydroxy-vitamin D levels with semen and hormonal parameters.

Authors:  Ahmad O Hammoud; A Wayne Meikle; C Matthew Peterson; Joseph Stanford; Mark Gibson; Douglas T Carrell
Journal:  Asian J Androl       Date:  2012-10-08       Impact factor: 3.285

Review 5.  Sperm bauplan and function and underlying processes of sperm formation and selection.

Authors:  Maria Eugenia Teves; Eduardo R S Roldan
Journal:  Physiol Rev       Date:  2021-04-21       Impact factor: 37.312

6.  Dynamic alterations in the paternal epigenetic landscape following fertilization.

Authors:  Timothy G Jenkins; Douglas T Carrell
Journal:  Front Genet       Date:  2012-07-31       Impact factor: 4.599

Review 7.  Assisted reproduction treatment and epigenetic inheritance.

Authors:  A P A van Montfoort; L L P Hanssen; P de Sutter; S Viville; J P M Geraedts; P de Boer
Journal:  Hum Reprod Update       Date:  2012-01-19       Impact factor: 15.610

Review 8.  Effects of increased paternal age on sperm quality, reproductive outcome and associated epigenetic risks to offspring.

Authors:  Rakesh Sharma; Ashok Agarwal; Vikram K Rohra; Mourad Assidi; Muhammad Abu-Elmagd; Rola F Turki
Journal:  Reprod Biol Endocrinol       Date:  2015-04-19       Impact factor: 5.211

9.  Assessment of chromatin maturity in human spermatozoa: useful aniline blue assay for routine diagnosis of male infertility.

Authors:  Afifa Sellami; Nozha Chakroun; Soumaya Ben Zarrouk; Hanen Sellami; Sahbi Kebaili; Tarek Rebai; Leila Keskes
Journal:  Adv Urol       Date:  2013-10-03

Review 10.  Impact of sperm DNA chromatin in the clinic.

Authors:  Dimitrios Ioannou; David Miller; Darren K Griffin; Helen G Tempest
Journal:  J Assist Reprod Genet       Date:  2015-12-17       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.